Drugs / NTQ2494
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06049667 | Aug 2023 → Aug 2026 overdue | acute myeloid leukemia | Nanjing Chia-tai Tianqing Pharmaceutical | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTQ2494 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06049667 ↗ |
| Known as | NTQ2494 tablet | “NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor.” NCT06049667 ↗ |
| Action | Inhibit | “an AXL kinase inhibitor” NCT06049667 ↗ |
| Route | Oral | “administered orally” NCT06049667 ↗ |
| Target | AXL | “an AXL kinase inhibitor” NCT06049667 ↗ |